Vaccines against cervical cancer

Bibliography

• FERLAY J, BRAY F, PISANI P, PARKIN DM: Clobocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press, Lyons, France (2001).
   Google Scholar
• KURMAN RJ, HENSON DE,HERBST AL et al.: Interim guidelines for management of abnormal cervical cytology. JAMA (1994) 271(23):1866–1869.
   Google Scholar
• IARC: International Agency for Research on Cancer: Human Papillomawiuses(HPV).IARC, Lyon, France (1995).
   Google Scholar
• ZUR HAUSEN H, DE VILLIERS EM, GISSMANN L: Papillomavirus infections and human genital cancer. Cynecol. Oncol. (1981) 12(2 Pt 2):S124–S128.
   Google Scholar
• HOWLEY PM: Papillomaviridae: the viruses and their replication. In: Fields Virology Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, Philadelphia, USA (1996):2045–2076.
   Google Scholar
• NOBBENHUIS MA,WALBOOMERS JM,HELMERHORST TJ et al.: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 354(9172):20–25.
   Google Scholar
• BOSCH FX, MANOS MM, MUNOZ N et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. .1. Natl. Cancer Inst. (1995) 87(11):796–802.
   Google Scholar
• LO KW, WONG YF, CHAN MK et al.: Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. hat. Cancer (2002) 100(3):327–331.
   Web of Science ®Google Scholar
• CHRISTENSEN ND, KREIDER JVV: Antibody-mediated neutralization in vivo ofinfectious papillomaviruses.Virol. (1990)64(7):3151–3156.
   Web of Science ®Google Scholar
• ••Article reporting that HPV capsids carryneutralising epitopes.
   Google Scholar
• ZHOU J, SUN XY, STENZEL DJ, FRAZER IH: Expression of vaccinia recombinant HPV 16 Li and L2 ORFproteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology(1991) 185(1):251–257.First report of a study demonstrating that HPV VLPs can be expressed recombinantly and that expression of capsid proteins form VLPs. This finding prepared the field for the development of prophylacticHPV vaccines.
   Google Scholar
• HOFMANN KJ, COOK JC, JOYCE JG et al.: Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology (1995) 209 (2):506–518.
   PubMed Web of Science ®Google Scholar
• KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLER JT: Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Nati Acad. Sci. USA (1992) 89(24):12180–12184.
   PubMed Web of Science ®Google Scholar
• JANSEN KU, ROSOLOWSKY M, SCHULTZ LD et al.: Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 13(16):1509–1514.
   PubMed Web of Science ®Google Scholar
• BREITBURD F, KIRNBAUER R, HUBBERT NL et al.: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. I. Vim/. (1995) 69(6):3959–3963.
   Google Scholar
• SUZICH JA, GHIM SJ, PALMERHILL FJet al.: Systemic immunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Proc. Nati Acad. Sci. USA (1995) 92(25):11553–11557.
   Google Scholar
• KIRNBAUER R, CHANDRACHUD LM, O'NEIL BW et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 219(1):37–44.
   Google Scholar
• TOBERY TW, SMITH JF, KUKLIN N et al.: Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine (2003) 21:1539–1547.
   PubMed Web of Science ®Google Scholar
• PALKER TJ, MONTEIRO JM,MARTIN MM et al.: Antibody, cytoldne and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine (2001) 19(27):3733–3743.
   Google Scholar
• SMITH IF, SKULSKY D, BRYAN D et al.: HPV VLP vaccine formulations with adjuvants increase immune response. 21st International Conference & Clinical Workshop Papilloinavirus 2004. Mexico City, Mexico (20–26 February 2004).
   Google Scholar
• HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 Li virus-like particle vaccine. J. Nati Cancer Inst. (2001) 93(4):284–292.
   PubMed Web of Science ®Google Scholar
• •First published study demonstrating that immunisation with HPV 16 VLPs expressed in insect cells induces high-titred neutralising antibody responses in humans.
   Google Scholar
• EVANS TG, BONNEZ W, ROSE RC et al.: A Phase I study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. (2001) 183(10):1485–1493.
   PubMed Web of Science ®Google Scholar
• BROWN DR, BRYAN IT,SCHROEDER JM et al.: Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 Li virus-like particles: correlation with competitiveradioimmunoassay titer. J. Infect. Dis. (2001) 184(9):1183–1186.
   Google Scholar
• BROWN DR, FIFE KH, WHEELER CM et al.: Early assessment of the efficacy of a human papillomavirus type 16 Li virus-like particle vaccine. Vaccine (2004) 22:2936–2942.
   PubMed Web of Science ®Google Scholar
• FIFE KH, WHEELER CM,KOUTSKY LA et al.: Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 22:2943–2952.
   Google Scholar
• •First clinical report showing that antibody responses to HPV 16 and 11 VLPs expressed in yeast persisted in the vast majority of immunised individuals well above levels induced by natural immunity.
   Google Scholar
• KOUTSKY LA, AULT KA,WHEELER CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl. J. Med. (2002) 347(21):1645–1651.
   Google Scholar
• ••First report of a randomised,placebo-controlled trial demonstrating that systemic immunisation with an HPV VLP-based vaccine was 100% efficacious in protecting young women against HPV infection and disease.
   Google Scholar
• FERRIS D: The GSK HPV 16/18 VLP vaccine - preliminary efficacy results. Eurogin 2003. Paris, France (13–16 April 2003).
   Google Scholar
• BURK RD, HO GY, BEARDSLEY L et al.: Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J. Infect. Dis. (1996) 174(4):679–689.
   PubMed Web of Science ®Google Scholar
• WINER RL, LEE SK, HUGHES JP et al.: Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am. J. Epideiniol. (2003) 157(3):218–226.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Sexually transmitted infections quarterly report: anogenital warts and HSV infection in England and Wales. Commun. Dis. Rep. CDR Weekly (2001) 11(35):11–15.
   Google Scholar
• BOTTIGER M, FORSGREN M: Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine (1997) 15(14):1538–1544.
   PubMed Web of Science ®Google Scholar
• KULASINGAM SL, MYERS ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 290(6):78i-789.
   Google Scholar
• GOLDIE SJ, KOHLI M, GRIMA D et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/ 18 vaccine. J. Nati Cancer Inst. (2004) 96(8):604–615.
   PubMed Web of Science ®Google Scholar
• SCOTT M, NAKAGAWA M,MOSCICKI AB: Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. (2001) 8(2):209–220.
   PubMedGoogle Scholar
• COLEMAN N, BIRLEY HD,RENTON AM et al.: Immunological events in regressing genital warts. Am. J. Clin. Pathol. (1994) 102(6):768–774.
   Google Scholar
• DE JONG A, VAN POELGEEST MI, VAN DER HULST JM et al.: Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. (2004) 64(15):5449–5455.
   Google Scholar
• FRAZER IH: Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev Immunol. (2004) 4(1):46–54.
   PubMed Web of Science ®Google Scholar
• DE JONG A, T ON, KHAN AY et al.: Enhancement of human papillomavirus (HPV) type 16 E6 and El-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 20:3456–3464.
   PubMed Web of Science ®Google Scholar
• GOLDSTONE SE, FIFE K, FINE P et al.: Durable clearance of genital warts following HspE7 immunization. 20th International Papillomavims Conference (HPV 2002).Paris, France (8 October 2002).
   Google Scholar
• GOLDSTONE SE, PALEFSKY JM, WINNETT MT, NEEFE JR: Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum (2002) 45(4):502–507.
   PubMed Web of Science ®Google Scholar
• DERKAY CS, ARNOLD J, BOWER C et al.: HspE7 treatment of pediatric recurrent respiratory papillomatosis (RRP): final results of an open-label trial. 21st International Papilloma virus Conference (HPV 2004). Mexico City, Mexico (26 February 2004).
   Google Scholar
• MUDERSPACH L, WILCZYNSKI S, ROMAN L et al.: A Phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16positive. Clin. Cancer Res. (2000) 6(9):3406–3416.
   PubMed Web of Science ®Google Scholar
• GARCIA F, PETRY KU,MUDERSPACH L et al: ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecel (2004) 103(2):317–326.
   PubMed Web of Science ®Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO M et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347(9014):1523–1527.
   PubMed Web of Science ®Google Scholar
• DAVIDSON EJ, BOS WELL CM, SEHRP et al.: Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. (2003) 63(18):6032–6041.
   PubMed Web of Science ®Google Scholar
• CORONA GUTIERREZ CM, TINOCO A, NAVARRO T et al.: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Thar: (2004) 15(5):421–431.
   PubMed Web of Science ®Google Scholar
• BALDWIN PJ, VAN DER BURG SH, BOSWELL CM et al.: Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. (2003) 9(105205–5213.
   Google Scholar
• SMYTH LJ, VAN POELGEEST MI, DAVIDSON EJ et al.: Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. (2004) 10(9):2954–2961.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/01/ minutes/3805m1.pdfVaccines and Related Biological Products Advisory Committee: Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD, USA.
   Google Scholar